Irene Cavattoni
Overview
Explore the profile of Irene Cavattoni including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
448
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bar M, El Anbari M, Rinchai D, Toufiq M, Kizhakayil D, Manjunath H, et al.
Cancers (Basel)
. 2025 Mar;
17(5).
PMID: 40075650
Graft versus host disease (GVHD) and the graft versus tumor (GVT) effect after allogeneic hematopoietic cell transplantation (allo-HCT) result from complex interactions between the donor immune system and the recipient...
2.
Ahmed N, Cavattoni I, Villiers W, Cugno C, Deola S, Mifsud B
Front Genet
. 2024 Oct;
15:1442539.
PMID: 39399221
Relapse remains a determinant of treatment failure and contributes significantly to mortality in acute myeloid leukemia (AML) patients. Despite efforts to understand AML progression and relapse mechanisms, findings on acquired...
3.
Bassan R, Pavoni C, Intermesoli T, Spinelli O, Tosi M, Audisio E, et al.
Blood Cancer J
. 2020 Nov;
10(11):119.
PMID: 33188164
An updated strategy combining pediatric-based chemotherapy with risk-oriented allogeneic hematopoietic cell transplantation (HCT) was evaluated in Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph- ALL) and compared with a published control series....
4.
Patriarca F, Sperotto A, Lorentino F, Oldani E, Mammoliti S, Isola M, et al.
Front Oncol
. 2020 Nov;
10:572918.
PMID: 33178602
We conducted a retrospective multicenter study including pediatric and adult patients with acute leukemia (AL) who received donor lymphocyte infusions (DLIs) after allogeneic hematopoietic stem cell transplantation (HCT) between January...
5.
Caprioli C, Lussana F, Salmoiraghi S, Cavagna R, Buklijas K, Elidi L, et al.
Haematologica
. 2020 Aug;
106(10):2578-2587.
PMID: 32855275
Secondary acute myeloid leukemia (sAML) after myelodysplastic or myeloproliferative disorders is a high-risk category currently identified by clinical history or specific morphological and cytogenetic abnormalities. However, in the absence of...
6.
Salmoiraghi S, Cavagna R, Zanghi P, Pavoni C, Michelato A, Buklijas K, et al.
Cancers (Basel)
. 2020 Aug;
12(8).
PMID: 32796597
By way of a Next-Generation Sequencing NGS high throughput approach, we defined the mutational profile in a cohort of 221 normal karyotype acute myeloid leukemia (NK-AML) enrolled into a prospective...
7.
Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, et al.
Blood Adv
. 2019 Apr;
3(7):1103-1117.
PMID: 30948365
Here we evaluated whether sequential high-dose chemotherapy (sHD) increased the early complete remission (CR) rate in acute myelogenous leukemia (AML) compared with standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy. This study enrolled 574...
8.
Introna M, Lussana F, Algarotti A, Gotti E, Valgardsdottir R, Mico C, et al.
Biol Blood Marrow Transplant
. 2017 Jul;
23(12):2070-2078.
PMID: 28712935
Seventy-four patients who relapsed after allogeneic stem cell transplantation were enrolled in a phase IIA study and treated with the sequential infusion of donor lymphocyte infusion (DLI) followed by cytokine-induced...
9.
Salmoiraghi S, Guinea Montalvo M, Ubiali G, Tosi M, Peruta B, Zanghi P, et al.
Haematologica
. 2016 Mar;
101(6):e245-8.
PMID: 26992948
No abstract available.
10.
Rambaldi A, Grassi A, Masciulli A, Boschini C, Mico M, Busca A, et al.
Lancet Oncol
. 2015 Oct;
16(15):1525-1536.
PMID: 26429297
Background: The standard busulfan-cyclophosphamide myeloablative conditioning regimen is associated with substantial non-relapse mortality in patients older than 40 years with acute myeloid leukaemia who are undergoing allogeneic stem-cell transplantation. Because...